A nanomedicine-based strategy for chemo-immunotherapy
(CIT) of glioblastoma (GBM), which has the worst prognosis among
brain tumors, was successfully developed. In vivo experiments
demonstrated that the combined use of epirubicin-encapsulating
nano-micelles (Epi/m) with immune checkpoint inhibitors (ICI)
eradicated PTEN-negative GBM, which is highly resistant to ICI
alone. Due to the synergistic effects of Epi/m plus ICI
combination, the number of tumor-infiltrating T cells (TIL) and
other antitumor immune cells significantly increased to kill cancer
cells effectively.
Epirubicin-loaded nanomedicines beat immune checkpoint
blockade resistance in glioblastoma
